Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics Corp announced that its CEO, Dr. Patrice Rioux, will present at the UMDF’s Mitochondrial Medicine 2025 Conference, highlighting the company’s leading clinical programs in MELAS and Leigh Syndrome Spectrum. The presentation will focus on their novel thiol drug, TTI-0102, which is in Phase 2 clinical trials in Europe and the U.S. The drug is designed to enhance intracellular levels of glutathione and taurine to combat oxidative stress, a core issue in mitochondrial disorders. This announcement underscores Thiogenesis’ commitment to advancing treatments for mitochondrial diseases and may strengthen its position in the biopharmaceutical industry.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company focused on developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders.
Average Trading Volume: 32,360
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$36.12M
See more data about TTI stock on TipRanks’ Stock Analysis page.